TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02924766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive apalutamide 240 mg (4\*60 mg) once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Participants will receive 1000 mg (4\*250mg) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive 10 mg (1\*5 mg twice daily).
Study: NCT02231970

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic sleeve gastroplasty
Description: To perform endoluminal gastric volume reduction by the Endoscopic sleeve gastroplasty
Study: NCT03407976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib oral daily at starting dose 1, Dose Level 2 or Dose Level 3 in phase I, and then whichever is the maximum tolerated dosage will be used for all Phase II patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Q3 weeks IV
Study: NCT03188003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Movement Techniques based on mobilization
Description: 10 sessions will be held twice a week, with each session taking an average of 50 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Movement Techniques based on stabilization
Description: 10 sessions will be held twice a week, with each session taking an average of 50 minutes.
Study: NCT03725566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
Study: NCT03444246

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine free diet group
Description: 120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal iodine diet group
Description: 120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal iodine diet group
Description: 120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
Study: NCT05972668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Apps
Description: The intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits
Study: NCT04009252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D Model Education
Description: A 3D model of the patients ankle fracture will be printed and used as a teaching tool to discuss long-term outcomes and potential complications.
Study: NCT02390323

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Sympathetic Block
Description: A lumbar sympathetic block is an injection in the middle of the lower back, toward the left or right side. The lumbar sympathetic nerves are a small bundle of nerves that carries sympathetic nerve signals from the lower extremities. In some instances, certain injuries to the lower extremities can cause a burning, unusual pain called complex regional pain syndrome or reflex sympathetic dystrophy. Injecting a small amount of local anesthetic on the lumbar sympathetic nerves can identify whether or not this pain is carried by the sympathetic nervous system.
Study: NCT01389401

Intervention type: DRUG
Intervention: omeprazole
Description: omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes

Intervention type: DRUG
Intervention: omeprazole
Description: omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
Study: NCT02390323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin conductance algesimeter
Description: The real-time changes in skin conductance indices can be monitored at the skin level, by use of non-invasive electrodes attached to the skin (similar to EKG electrodes) connected to the skin conductance algesimeter. A computer program analyzes the data and produces a real-time graphic and numeric data demonstrating the skin conductance response. The initiation of successful sympathetic blockade can cause rapid cessation of the skin sympathetic activity that leads to a decrease in skin conductance within seconds.
Study: NCT02299128

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical Therapy Treatment
Study: NCT01389401

Intervention type: DRUG
Intervention: omeprazole
Description: omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
Study: NCT00198861

Intervention type: OTHER
Intervention: Injection and Non-Injection Drug Users
Description: (1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
Study: NCT02082223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions to improve preop QOL/resilience deficits
Description: Identify patients' and patients' care givers quality of life/resilience deficits and supply information and resources prior to undergoing complex GI surgery.
Study: NCT02413736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400 mg/day
Study: NCT02299128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Treatment
Study: NCT02014480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Umeclidinium 62.5 mcg
Description: Umeclidinium 62.5 mcg once daily in the morning via NDPI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vilanterol 25 mcg
Description: Vilanterol 25 mcg once daily in the morning via NDPI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol 62.5/25 mcg
Description: Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
Study: NCT03114124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIFI Catheter
Description: Multielectrode Catheter: standard ablation catheter that has the ability to record low and high frequency signals with high fidelity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ablation Catheter
Description: Standard of care for patients with certain cardiac arrhythmias.
Study: NCT02518594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: 200mg micronized vaginal progesterone softgel capsule, daily from randomization to \< 35 wks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo softgel capsule, daily from randomization to \< 35 wks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arabin Pessary
Description: Placement management from randomization to \< 35 wks
Study: NCT01616940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Peer Intervention
Description: Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:~* Introduction and Assessment~* HIV Transmission \& Viral Life Cycle~* Effective Communication and Self-Advocacy~* Understanding Lab Values~* HIV Medications~* Drug Resistance \& Adherence, and Understanding \& Managing Side Effects~* Disclosure and Stigma~* Harm \& Risk Reduction~Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:~* Are any services needed?~* Have referrals or appointments been made?~* Does patient need accompaniment to a visit?~* Connect patient with services as needed.~* Appointment reminders.~* Overall well-being?~* Schedule next peer contact.
Study: NCT04216940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical preparation of root canal system
Description: Assess the pain intensity in a two-visit treatment of molars with irreversible pulpitis after instrumentation with two different rotary Nickle Titanium systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical preparation of root canal system
Description: Assess the pain intensity in a two-visit treatment of molars with irreversible pulpitis after instrumentation with two different rotary Nickle Titanium systems
Study: NCT00715364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTx™-265: rhCG, then rEPO
Description: * rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: * Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation
Study: NCT01143051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine inhalation aerosol
Description: Single dose 220 mcg/inhalation, 10 inhalations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine inhalation aerosol
Description: HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine inhalation aerosol
Description: HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
Study: NCT04371822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SnPP Protoporphyrin plus Sunlight exposure
Description: SnPP Protoporphyrin plus Sunlight exposure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SnPP Protoporphyrin plus Sunlight exposure
Description: SnPP Protoporphyrin and Sunlight exposure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SnPP Protoporphyrin plus Sunlight exposure
Description: SnPP Protoporphyrin plus Sunlight exposure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
Description: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: No Intervention
Study: NCT00856141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phacoemulsifcation
Description: A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsifcation
Description: A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
Study: NCT02186288

Intervention type: OTHER
Intervention: High-flow nasal cannula oxygen
Study: NCT01958073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Estrogen Vaginal Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Ring

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02881918

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
Study: NCT00474266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612 (Nimenrix)
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612 (Nimenrix)
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix-Tetra
Description: 2-dose subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix-Tetra
Description: 2-dose subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix-Tetra
Description: 2-dose subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix-Tetra
Description: 2-dose subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec
Description: Single dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec
Description: Single dose intramuscular injection
Study: NCT01476033

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: nutraceutical group
Description: 6 capsules of supplement or placebo for 8wk
Study: NCT03513055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse inject premixed insulin
Description: nurse inject premixed insulin，coaching in the injection technique
Study: NCT00318877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After school team sports program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: After school health education program
Study: NCT01920022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Day one of medical abortion
Study: NCT01476033

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutraceutical group
Description: 6 capsules of supplement or placebo for 8wk
Study: NCT01920022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Day one of medical abortion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etonorgestrel
Study: NCT02352935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife LEDC System
Description: 90 pulses of 70 microseconds each in duration will be administered per electrode pair
Study: NCT01654172

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Flavanol Cocoa
Description: Total daily flavanol intake provided by the high flavanol drink is \~900mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Flavanol Cocoa
Study: NCT04556071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally once a day continuously throughout each 21-days cycle. The initial dose will be based on the participant's basal body weight or platelet count. Participants with basal body weight≥77 kg and basal platelet count of≥150,000/microliter (μL) will take 300 mg daily. While participants with basal body weight\<77 kg and/or basal platelet count \<150,000/μL will take 200 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The dose of Bevacizumab will be 15 mg/kg that administered via a 30-minute intravenous infusion on day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death.
Study: NCT03369197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Mask
Description: Nasal anesthesia mask which covers the nose and attaches to the anesthesia circuit, allowing for variable positive pressure by setting the pop-off valve
Study: NCT01213342

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid
Description: Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:~* EPA (Eicosapentaenoic Acid) 1300mg~* DHA (Docosahexaenoic Acid) 900 mg~* Other Omega-3's 360mg~* Total Omega 3's 2560 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soybean Soft Gels
Description: Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).
Study: NCT05510999

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of placebo will be taken twice daily for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water soluble pollen extract fraction
Description: Each capsule contains 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (360 mg/day) for 24 weeks.
Study: NCT01219920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
Study: NCT04219332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subserosa injection of indocyanine green
Description: After preoperative exploration, the indocyanine green powder (Dandong Yichuang Pharmaceutical Co) is dissolved in 0.5 mg/ml of sterile water and the prepared solution (1.5 ml for each point) is injected along the subserosal of the stomach at 6 specific points along the lesser and greater curvature of the stomach.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: submucosal injection of indocyanine green
Description: One day before surgery, 1.25 mg/ml indocyanine green (Dandong Yichuang Pharmaceutical Co) was prepared in sterile water and 0.5 ml of the solution was injected into the submucosal layer at 4 quadrants around the primary tumor, amounting to 2.5 mg of indocyanine green.
Study: NCT01837979

Intervention type: PROCEDURE
Intervention: cell-free fetal DNA
Description: cell-free fetal DNA for DBS and maternal serum screening high risk pregnant women. Comparison of multiple Down's syndrome screening tests.

Intervention type: PROCEDURE
Intervention: cell-free fetal DNA
Description: cell-free fetal DNA for DBS and maternal serum screening high risk pregnant women. Comparison of multiple Down's syndrome screening tests.
Study: NCT03348020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Donation
Description: Subjects will donate blood within \~1 month after their baseline clinical trial. Subjects will report to the Substrate Metabolism Laboratory between 24 and 72 hours following blood donation. A finger-stick will be performed for the measurement of hemoglobin concentration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Donation
Description: Subjects will donate blood within \~1 month after their baseline clinical trial. Subjects will report to the Substrate Metabolism Laboratory between 24 and 72 hours following blood donation. A finger-stick will be performed for the measurement of hemoglobin concentration.
Study: NCT04975360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: The 160 mg caffeine pulsatile-release formulation was manufactured using a drug layering process. Caffeine and the excipients are dispersed in the coating media and then sprayed onto inert microcrystalline cellulose spheres using a fluid bed through a Wurster tube with continuous inlet air that dries the liquid in the dispersion, to obtain various layers consisting of caffeine and release-controlling polymers. The applied release-controlling polymeric system is based on methacrylate copolymers, which control the release of caffeine in pH-dependent and pH-independent manner. The release mechanism of the polymeric system is mainly driven by the swellability and permeability of the copolymers. The final micropellets are then encapsulated into hydroxypropylmethylcellulose capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical hydroxypropylmethylcellulose capsules without containing caffeine micropellets.
Study: NCT05581758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral Tablet
Study: NCT01813578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intensive aerobic and muscle endurance exercise
Study: NCT00705081

Intervention type: DRUG
Intervention: ezetimibe
Description: 10 mg once daily

Intervention type: DRUG
Intervention: ezetimibe
Description: 10 mg once daily

Intervention type: DRUG
Intervention: statin

Intervention type: DRUG
Intervention: statin
Study: NCT04904887

Intervention type: PROCEDURE
Group type: OTHER
Intervention: phacoemulsification
Description: phacoemulsification with implantation of EYEHANCE IOL
Study: NCT02968251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Washing Program (HWP)
Description: HWP consists of integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
Study: NCT01058889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedical device
Description: Monitoring of blood glucose,insulin dose, blood pressure, lifestyle factors with the telemedical device. Monitoring of system availability, percentage of data transfer, acceptance.

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Telemedical device
Description: Monitoring of blood glucose,insulin dose, blood pressure, lifestyle factors with the telemedical device. Monitoring of system availability, percentage of data transfer, acceptance.
Study: NCT04290884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: The recruited patients will be randomly assigned to two groups, 50% chance to the experimental group (use of tranexamic acid) and 50% chance to the control group (use of normal saline). After the reduction of the intertrochanteric fracture, 10ml of tranexamic acid is injected under the deep fascia around the fracture area before inserting a drain. As for the control group, 10ml of normal saline is injected instead. Blood will be taken on the third day post operation, and the patient will be seen at 6 weeks, and 3 months.
Study: NCT00770796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80 mg die

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo